Holdings of BIOTECHNOLOGY ULTRASECTOR PROFUND
ProFunds · Original filing · Compare with another fund · Report an error
- Net assets
- 182.6M $ including 132M $ in equities, 72.3 %
- Positions
- 145 in 6 countries
- Top ten
- 10.7 % of net assets
- Filed on
- Apr 30, 2026
Portfolio shape
Positions
| Rank | Company | Shares | Value | Weight |
|---|---|---|---|---|
| 101 | Precigen Inc | 106,333 | 442.3K $ | 0.24 % |
| 102 | SELLAS Life Sciences Group Inc | 83,087 | 411.3K $ | 0.23 % |
| 103 | Tyra Biosciences Inc | 11,611 | 403.5K $ | 0.22 % |
| 104 | Absci Corp | 80,266 | 399.3K $ | 0.22 % |
| 105 | Annexon Inc | 67,711 | 397.5K $ | 0.22 % |
| 106 | Kura Oncology Inc | 44,688 | 394.6K $ | 0.22 % |
| 107 | Sana Biotechnology Inc | 117,782 | 387.5K $ | 0.21 % |
| 108 | ArriVent Biopharma Inc | 12,409 | 385.8K $ | 0.21 % |
| 109 | ORIC Pharmaceuticals Inc | 38,468 | 380.1K $ | 0.21 % |
| 110 | Rigel Pharmaceuticals Inc | 12,551 | 362.7K $ | 0.20 % |
| 111 | Janux Therapeutics Inc | 25,227 | 362.5K $ | 0.20 % |
| 112 | CytomX Therapeutics Inc | 79,888 | 337.1K $ | 0.18 % |
| 113 | Savara Inc | 62,943 | 329.8K $ | 0.18 % |
| 114 | ARS Pharmaceuticals Inc | 39,185 | 323.7K $ | 0.18 % |
| 115 | ZENAS BIOPHARMA INC | 16,046 | 310K $ | 0.17 % |
| 116 | Cullinan Therapeutics Inc | 23,146 | 302.1K $ | 0.17 % |
| 117 | Xencor Inc | 25,177 | 300.4K $ | 0.16 % |
| 118 | Ironwood Pharmaceuticals Inc | 72,159 | 297.7K $ | 0.16 % |
| 119 | Sionna Therapeutics Inc | 7,374 | 285.4K $ | 0.16 % |
| 120 | Bicara Therapeutics Inc | 12,659 | 273.2K $ | 0.15 % |
| 121 | HYPERLIQUID STRATEGIES INC | 44,231 | 266.3K $ | 0.15 % |
| 122 | Prime Medicine Inc | 71,813 | 254.6K $ | 0.14 % |
| 123 | Vor BioPharma Inc | 16,824 | 241.1K $ | 0.13 % |
| 124 | Emergent BioSolutions Inc | 28,381 | 233.6K $ | 0.13 % |
| 125 | REGENXBIO Inc | 24,609 | 220.7K $ | 0.12 % |
| 126 | Vanda Pharmaceuticals Inc | 30,747 | 218.3K $ | 0.12 % |
| 127 | First Tracks Biotherapeutics Inc | 9,076 | 211.2K $ | 0.12 % |
| 128 | 4D Molecular Therapeutics Inc | 23,783 | 211K $ | 0.12 % |
| 129 | Allogene Therapeutics Inc | 94,053 | 200.3K $ | 0.11 % |
| 130 | Altimmune Inc | 77,039 | 200.3K $ | 0.11 % |
| 131 | Verastem Inc | 36,349 | 198.5K $ | 0.11 % |
| 132 | Prothena Corp PLC | 17,744 | 196.2K $ | 0.11 % |
| 133 | Lexeo Therapeutics Inc | 33,610 | 191.4K $ | 0.10 % |
| 134 | Myriad Genetics Inc | 38,978 | 185.1K $ | 0.10 % |
| 135 | Arbutus Biopharma Corp | 40,924 | 171.9K $ | 0.09 % |
| 136 | Rocket Pharmaceuticals Inc | 47,039 | 163.7K $ | 0.09 % |
| 137 | Ocugen Inc | 94,238 | 163K $ | 0.09 % |
| 138 | Anavex Life Sciences Corp | 47,885 | 159.9K $ | 0.09 % |
| 139 | Akebia Therapeutics Inc | 108,964 | 150.4K $ | 0.08 % |
| 140 | Invivyd Inc | 102,029 | 142.8K $ | 0.08 % |
| 141 | MiMedx Group Inc | 41,188 | 138.4K $ | 0.08 % |
| 142 | Perspective Therapeutics Inc | 30,917 | 120.6K $ | 0.07 % |
| 143 | Compass Therapeutics Inc | 65,246 | 115.5K $ | 0.06 % |
| 144 | Replimune Group Inc | 39,465 | 101.4K $ | 0.06 % |
| 145 | DAMORA THERAPEUTICS INC | 1,693 | 43.4K $ | 0.02 % |
Sector breakdown
- Health care 14.1 %
- Unattributed 85.9 %
Titelia classification, company by company. The unattributed share stays visible.
Currency breakdown
- USD 100.0 %
The quoted currency of each line, as declared.
Country breakdown
- United States 95.2 %
- Ireland 1.5 %
- Switzerland 1.2 %
- Bermuda 1.1 %
- British Virgin Islands 0.5 %
- Netherlands 0.5 %
Shares computed on the equity sleeve.
| Rank | Country | Lines | Value | Share |
|---|---|---|---|---|
| 1 | United States | 139 | 125.7M $ | 95.23 % |
| 2 | Ireland | 2 | 2M $ | 1.53 % |
| 3 | Switzerland | 1 | 1.6M $ | 1.19 % |
| 4 | Bermuda | 1 | 1.4M $ | 1.10 % |
| 5 | British Virgin Islands | 1 | 653.4K $ | 0.50 % |
| 6 | Netherlands | 1 | 599.9K $ | 0.45 % |
Cite this page
Titelia. "Holdings of BIOTECHNOLOGY ULTRASECTOR PROFUND". https://titelia.com/en/funds/S000003107